Cotización Biocept - BIOC

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Último Precio

0.4349

Postura de Compra

0.37

Postura de Venta

0.3799

Volume Operado de la Acción

0.00 Rango del Día 0.00

0.00 Rango de 52 semanas 0.00

Precio Anterior

0.4349

Precio de Apertura

Hora

Última hora de negociación

Volumen promedio (3 m)

Volumen financiero

Precio Promedio Ponderado

Form 8-K - Current report

Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer...

Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for CNSide™ with Plus...

Biocept to Participate in the H.C. Wainwright Global Investment Conference

Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, announces that management will participate in the H.C...

Biocept to Hold Business Update Conference Call on August 30, 2023

Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call on August 30, 2023, beginning at 4:00 p.m. Eastern time (1:00 p.m. Pacific time) to provide a business update and to answer...

Form 8-K - Current report

Biocept Reports Second Quarter 2023 Financial Results

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2023 and provides a...

Biocept’s CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer Conference

Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, announces that its CNSide cerebrospinal fluid assay was...

Biocept Announces the Passing of Board Chair M. Faye Wilson

Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”) announces that M. Faye Wilson, Board Chair, passed away unexpectedly on Monday, July 10. The Board of Directors and staff of Biocept...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

BIOC - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Biocept?

El precio actual de las acciones de Biocept es US$ 0.4349

¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Biocept?

Biocept ha negociado en un rango de US$ 0.00 a US$ 0.00 durante el último año

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
SLXNSilexion Therapeutics Corporation	US$ 1.069 (84.31%)	193.05M
RNAZTransCode Therapeutics Inc	US$ 12.5475 (83.71%)	33.83M
DGNXDiginex Ltd	US$ 16.83 (78.66%)	1.15M
TRIBTrinity Biotech PLC	US$ 1.14 (50.00%)	105.55M
YIBOPlanet Image International Ltd	US$ 4.52 (46.75%)	52.62M
LPTXLeap Therapeutics Inc	US$ 0.65655 (-70.82%)	10.4M
STSSSharps Technology Inc	US$ 0.467475 (-67.98%)	16.42M
SABSSAB Biotherapeutics Inc	US$ 2.365 (-45.76%)	1.21M
TECXTectonic Therapeutic Inc	US$ 23.52 (-42.88%)	756.25k
INKTMiNK Therapeutics Inc	US$ 5.06 (-42.75%)	211.95k
NVDANVIDIA Corporation	US$ 126.55 (6.87%)	414.4M
HEPAHepion Pharmaceuticals Inc	US$ 0.2252 (36.48%)	297.46M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.5458 (32.44%)	269.03M
SLXNSilexion Therapeutics Corporation	US$ 1.07 (84.48%)	193.05M
TRIBTrinity Biotech PLC	US$ 1.14 (50.00%)	105.55M